Efficacy and Safety of Tasimelteon Compared With Placebo in Totally Blind Subjects With Non-24-Hour Sleep-Wake Disorder

Non-24-Hour Sleep-Wake Disorder Clinical Trial

Official title:

A Multicenter, Randomized, Double-Mask, Placebo-Controlled, Parallel Study to Investigate the Efficacy and Safety of 20 mg Tasimelteon Versus Placebo in Totally Blind Subjects With N24HSWD Followed by an OLE Phase

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01163032
• Other study ID #: VP-VEC-162-3201
• Status: Completed
• Phase: Phase 3
• First received: July 2, 2010
• Last updated: October 15, 2014
• Start date: August 2010
• Est. completion date: November 2012

Study information

• Verified date: October 2014
• Source: Vanda Pharmaceuticals
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of a six month double-mask treatment of tasimelteon or placebo in male and female subjects with Non-24-Hour Sleep-Wake Disorder

Description:

Non-24-Hour Sleep-Wake Disorder (N24HSWD) occurs when individuals, primarily those without light perception, are unable to synchronize their endogenous circadian pacemaker to the 24-hour light-dark cycle, and the timing of their circadian rhythm instead reflects the intrinsic period of their endogenous circadian pacemaker. As a result, the circadian rhythm of sleep-wake propensity in these individuals moves gradually later and later each day if there circadian period is > 24 hours and earlier and earlier if < 24 hours. These individuals will be able to sleep well at night when their sleep-wake propensity rhythm is approximately aligned with the 24-hour light-dark and social cycle. However, after a short time, the endogenous sleep-wake propensity rhythm and the 24-hour light-dark cycle will move out of synchrony with each other, and they may have difficulty falling asleep until well into the night. In addition to problems sleeping at the desired time, the subjects experience daytime sleepiness and daytime napping.

This will be a multicenter, randomized, double-masked, placebo-controlled, parallel study. The study has two phases: the pre-randomization phase followed by either the randomization phase or the open-label extension (OLE). The pre-randomization phase comprises a screening visit where subject's initial eligibility will be evaluated, a circadian period (τ) estimation segment, and a variable-length in-phase transition segment in which subjects will wait to start treatment until their circadian phase is aligned with their target bedtime. Subjects that meet all entry criteria for the study will enter the randomization phase. During the randomization phase, subjects will be asked to take either 20 mg tasimelteon or placebo approximately 1 hour prior to their target bedtime for 26 weeks in a double-masked fashion. Subjects who have a τ greater than 24.0 and meet all entry criteria but that are ineligible for the randomization phase due to their τ estimate may be given the opportunity to participate in the OLE phase. During the OLE phase, subjects will take open-label 20mg tasimelteon for 26 weeks.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 136
• Est. completion date: November 2012
• Est. primary completion date: November 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Ability and acceptance to provide informed consent;

• No perception of light by the subject's own report;

• Diagnosis of N24HSWD as determined by:

1. History (within the last 3 months) of trouble sleeping at night difficulty initiating sleep or staying asleep), difficulty awakening in the morning, or daytime sleepiness as determined by answering yes to at least one question in the Sleep Complaint Questionnaire and

2. Urinary aMT6s demonstrates a progressive delay of the aMT6 acrophase time.

• Willing and able to comply with study requirements and restrictions including a commitment to a fixed 9-hour sleep opportunity during the study;

• Fluent in English;

Exclusion Criteria:

• Have a probable diagnosis of a current sleep disorder other than N24HSWD that is the primary cause of the sleep disturbance based on clinical investigator medical judgment;

• Current clinically significant cardiovascular, respiratory, neurologic, hepatic, hematopoietic, renal, gastrointestinal or metabolic dysfunction unless currently controlled and stable;

• History (within the 12 months prior to screening) of psychiatric disorders including Major Depressive Disorder, Generalized Anxiety Disorder, Axis II Disorders, delirium or any other psychiatric disorder that in the opinion of the clinical investigator would affect participation in the study or full compliance with study procedures;

• History of intolerance and/or hypersensitivity to melatonin or melatonin agonists;

• Worked night, rotating, or split (period of work, followed by break, and then return to work) shift work within 1 month of the screening visit or plan to work these shifts during the study;

• Unable to perform calls to the study IVR system to report questionnaire results;

• Exposure to any investigational drug, including placebo, within 30 days or 5 half lives (whichever was longer) of screening;

• Use of central nervous system prescription or OTC medications, other than melatonin, that affects the sleep-wake cycle

• Use of melatonin or melatonin agonist

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Non-24-Hour Sleep-Wake Disorder
• Sleep Disorders, Circadian Rhythm

Intervention

Drug:
• tasimelteon
20 mg tasimelteon capsules, PO daily for 6 months
• Placebo
Placebo capsules, PO daily for 6 months

Locations

Country	Name	City	State
Germany	Advanced Sleep Research GmbH	Berlin
Germany	Bergmannsheil University Hospital - Medical Clinic III	Bochum
Germany	Klinische-Forschung Hannover Mitte	Hannover
Germany	Universitaetsklinikum Glesen and Marburg gmbH/Schlaflabor - Sleep Lab University Marburg	Marburg
Germany	Bonomed Studiezentrum	Munich
United States	Michigan Head-Pain Neurological Institute	Ann Arbor	Michigan
United States	Sleep Disorders Center Of Georgia	Atlanta	Georgia
United States	Brigham and Women's Hospital	Boston	Massachusetts
United States	PAB Clinical Research Inc.	Brandon	Florida
United States	St. Luke's Sleep Medicine and Research Center (St. Louis Metropolitan Area)	Chesterfield	Missouri
United States	The Center for Sleep and Wake Disorders (Washington, D.C. Metropolitan Area)	Chevy Chase	Maryland
United States	Tri-State Sleep Disorders Center	Cincinnati	Ohio
United States	SleepMed, Inc. - Columbia	Columbia	South Carolina
United States	Radiant Research - Denver	Denver	Colorado
United States	Ohio Sleep Medicine Institute (Columbus Metropolitan Area)	Dublin	Ohio
United States	Suburban Lung Associates SC (Chicago Metropolitan Area)	Elk Grove Village	Illinois
United States	Todd J. Swick, M.D., P.A.	Houston	Texas
United States	Kendall South Medical Center, Inc.	Miami	Florida
United States	New York Eye and Ear Infirmary	New York	New York
United States	Lynn Health Science Institute	Oklahoma city	Oklahoma
United States	SDS Clinical Trials Inc.	Orange	California
United States	Ocean Sleep Disorders Center - Ormond Beach	Ormond Beach	Florida
United States	VA Palo Alto Health Care System/PAIRE (San Fransisco Bay Area)	Palo Alto	California
United States	Center For Sleep Medicine at Chestnut Hill Hospital	Philadelphia	Pennsylvania
United States	Pulmonary Associates, PA	Phoenix	Arizona
United States	Consolidated Clinical trials	Pittsburgh	Pennsylvania
United States	Columbia Research Group Inc.	Portland	Oregon
United States	St. Johns Sleep Disorder Center - St. Johns Medical Plaza	Santa Monica	California

Sponsors (1)

Lead Sponsor	Collaborator
Vanda Pharmaceuticals

Countries where clinical trial is conducted

United States,  Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Proportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of = 2 on N24CRS	Clinical response is defined as the coincident demonstration of entrainment (aMT6) and a score = 2 on the Non-24 Clinical Response Scale (N24CRS) which includes LQ-nTST, UQ-dTSD, MoST and CGI-C assessments. Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below).; LQ-nTST: >45 minutes increase in average nighttime sleep duration; UQ-dTSD: >45 minutes decrease in average daytime sleep duration; MoST: >30 minutes increase and a standard deviation <2 hours during double-masked phase (6 months); CGI-C: <2.0 from the average of D112 and Day 183 compared to baseline; For patients randomized to tasimelteon 20 mg and who also participated in the screening phase of Study 3203 (month 7 of treatment), the screening t from Study 3203 was used if the patient did not become entrained in Study 3201 but did become entrained during the screening phase of Study 3203.	6 months	No
Other	Proportion of Patients With a Clinical Response (Score of = 3 on N24CRS)	Non-24 Clinical Response Scale (N24CRS) was a 4-item scale which includes LQ-nTST, UQ-dTSD, MoST and CGI-C assessments. Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below).; LQ-nTST: >45 minutes increase in average nighttime sleep duration; UQ-dTSD: >45 minutes decrease in average daytime sleep duration; MoST: >30 minutes increase and a standard deviation <2 hours during double-masked phase (6 months); CGI-C: <2.0 from the average of D112 and Day 183 compared to baseline	6 months	No
Other	Proportion of Patients With a Clinical Response (Score of = 2 on N24CRS)	Non-24 Clinical Response Scale (N24CRS) was a 4-item scale which includes LQ-nTST, UQ-dTSD, MoST and CGI-C assessments. Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below).; LQ-nTST: >45 minutes increase in average nighttime sleep duration; UQ-dTSD: >45 minutes decrease in average daytime sleep duration; MoST: >30 minutes increase and a standard deviation <2 hours during double-masked phase (6 months); CGI-C: <2.0 from the average of D112 and Day 183 compared to baseline	6 months	No
Primary	Proportion of Patients Entrained as Assessed by Urinary aMT6	Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (t) was calculated using urinary aMT6s collected over four 48 hour periods , collected approximately 1 week apart for 4 separate weeks, during the screening and month 1 of the randomization phase of the trial. Entrainment was defined as having a post-baseline t value less than 24.1 and a 95% CI that included 24.0.	1 month	No
Primary	Proportion of Patients With a Clinical Response: Entrainment of aMT6 and Score of = 3 on N24CRS	Clinical response is defined as the coincident demonstration of entrainment (aMT6) and a score = 3 on the Non-24 Clinical Response Scale (N24CRS). N24CRS measures improvement in sleep-wake measures and overall functioning (LQ-nTST, UQ-dTSD, MoST and CGI-C). Each assessment is scored as a 1 or 0 depending on the pre-specified threshold (see below).; LQ-nTST: >45 minutes increase in average nighttime sleep duration; UQ-dTSD: >45 minutes decrease in average daytime sleep duration; MoST: >30 minutes increase and a standard deviation <2 hours during double-masked phase (6 months); CGI-C: <2.0 from the average of D112 and Day 183 compared to baseline; For patients randomized to tasimelteon 20 mg and who also participated in the screening phase of Study 3203 (month 7 of treatment), the screening t from Study 3203 was used if the patient did not become entrained in Study 3201 but did become entrained during the screening phase of Study 3203.	6 months	No
Secondary	Proportion of Patients Entrained as Assessed by Urinary Cortisol	Entrainment is a measure of synchronization of the master body clock to the 24-hour day. The circadian period (t) was calculated using urinary cortisol collected over four 48 hour periods, approximately 1 week apart for 4 separate weeks, during the screening and month 1 of the randomization phase of the trial. Entrainment was defined as having a post-baseline t value less than 24.1 and a 95% CI that included 24.0.	1 month	No
Secondary	Average Clinical Global Impression of Change (CGI-C)	CGI-C scores range from 1 (very much improved) to 7 (very much worse). The average post-randomization score was obtained for each patient by averaging the last 2 scheduled assessments (Day D112 and Day D183). Lower number indicates improvement.	Day 112 and 183	No
Secondary	Proportion of Responders With a Combined Sleep/Wake Response for LQ-nTST (= 90 Minutes) and UQ-dTSD (= 90 Minutes)	The sleep/wake response represents measurement of the combined improvement in the nighttime sleep duration and daytime sleep duration. Individuals that have an improvement in nighttime sleep and daytime sleep, defined as an increase of 90 minutes or more in the lower quartile of subjective nighttime total sleep time (LQ-nTST) and a decrease of 90 minutes or more in the upper quartile of daytime total sleep duration (UQ-dTSD) are considered to be a responder.	6 months	No
Secondary	Average Lower Quartile of Nights of Nighttime Total Sleep Time (LQ-nTST)	LQ-nTST measures the difference in average nighttime sleep during the patient's worst 25% of nights (shortest total nighttime sleep) between the randomized phase (6 months)and the screening phase (~ 6 weeks). The higher number indicates improvement.	6 months	No
Secondary	Average Upper Quartile of Days of Subjective Daytime Sleep Duration (UQ-dTSD)	UQ-dTSD measures the difference in average daytime sleep during the patient's worst 25% of days (longest total daytime sleep) between the randomized phase (6 months) and the screening phase (~ 6 weeks). Lower number indicates improvement.	6 months	No
Secondary	Average Midpoint of Sleep (MoST)	Midpoint of Sleep Timing (MoST) is the measurement of the average midpoint of sleep time relative to bedtime. The average MoST value will trend to 0 as an individual's sleep becomes more fragmented. Improvement is defined as an increase in the average.	6 months	No
Secondary	Number of Patients With a Treatment Emergent Adverse Event (Open Label Extension Phase Only)	Adverse events were recorded in the source documents from the time of the patient's informed consent signature until the end of the patient's study participation. An AE was defined as any untoward medical occurrence in a clinical investigation patient who does not necessarily have causal relationship with treatment.	6 months	Yes